DigestRedComo funciona
Red
/
Empresas
Io
No verificado

Ionis Pharmaceuticals, Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

81 Comunicados de prensa

Ver todos los comunicados de prensa
23/09/2026
Industria
Salud
Ciencia
Farmacéutica
Medicina - Varios
Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN)
Fuente
Ionis Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
22/09/2026
Industria
Farmacéutica
Sanidad
Salud
Higiene alimentaria
Comunicación
Biotecnología
Medicina - Varios
Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS
Fuente
Ionis Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
04/09/2026
Industria
Farmacéutica
Salud
Medicina - Varios
Cardiología
Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
Fuente
Ionis Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
03/09/2026
ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients
Fuente
Ionis Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
03/09/2026
Eventos
Web y redes sociales
Biotecnología
Farmacéutica
Salud
Ionis to present at upcoming investor conferences
Fuente
Ionis Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
20/08/2026
Web y redes sociales
Ferias y Congresos
Eventos
Salud
Medicina - Varios
Ciencia
Farmacéutica
Cardiología
Biotecnología
Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026
Fuente
Ionis Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
29/07/2026
Mercado laboral
Ciencia
Biotecnología
Farmacéutica
Sanidad
Salud
Ionis announces Dr. Frank Bennett, chief scientific officer, to retire
Fuente
Ionis Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
29/07/2026
Web y redes sociales
Telefonía
Mercado de valores
Salud
Biotecnología
Farmacéutica
Cardiología
Ionis reports second quarter 2026 financial results and highlights progress on key programs
Fuente
Ionis Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
15/07/2026
Salud
Biotecnología
Farmacéutica
Cardiología
Web y redes sociales
Telefonía
Finanzas
Mercado de valores
Ionis to hold second quarter 2026 financial results webcast
Fuente
Ionis Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
14/07/2026
Eventos
Industria
Salud
Biotecnología
Medicina - Varios
Farmacéutica
Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
Fuente
Ionis Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0